HTA202 Health Technology Assessment (HTA) and Reimbursement Decisions for the New Anti-IL-13 Monoclonal Antibody Lebrikizumab for Patients With Moderate to Severe Atopic Dermatitis (AD) in Europe
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.2027
https://www.valueinhealthjournal.com/article/S1098-3015(24)04890-3/fulltext
Title :
HTA202 Health Technology Assessment (HTA) and Reimbursement Decisions for the New Anti-IL-13 Monoclonal Antibody Lebrikizumab for Patients With Moderate to Severe Atopic Dermatitis (AD) in Europe
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)04890-3&doi=10.1016/j.jval.2024.10.2027
First page :
Section Title :
Open access? :
No
Section Order :
11493